Multiple Vaccine-elicited Nonneutralizing Antienvelope Antibody Activities Contribute to Protective Efficacy by Reducing Both Acute and Chronic Viremia Following Simian/human Immunodeficiency Virus SHIV89.6P Challenge in Rhesus Macaques

Overview

Journal J Virol

Publisher American Society for Microbiology

Date 2010 May 7

PMID 20444898

Citations 118

Authors

Peng Xiao

Jun Zhao

L Jean Patterson

Egidio Brocca-Cofano

David Venzon

Pamela A Kozlowski

Rachmat Hidajat

Thorsten Demberg

Marjorie Robert-Guroff

Affiliations

Soon will be listed here.

Abstract

We have shown that following priming with replicating adenovirus type 5 host range mutant (Ad5hr)-human immunodeficiency virus (HIV)/simian immunodeficiency virus (SIV) recombinants, boosting with gp140 envelope protein enhances acute-phase protection against intravenous simian/human immunodeficiency virus (SHIV)(89.6P) challenge compared to results with priming and no boosting or boosting with an HIV polypeptide representing the CD4 binding site of gp120. We retrospectively analyzed antibodies in sera and rectal secretions from these same macaques, investigating the hypothesis that vaccine-elicited nonneutralizing antibodies contributed to the better protection. Compared to other immunized groups or controls, the gp140-boosted group exhibited significantly greater antibody activities mediating antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cell-mediated viral inhibition (ADCVI) in sera and transcytosis inhibition in rectal secretions. ADCC and ADCVI activities were directly correlated with antibody avidity, suggesting the importance of antibody maturation for functionality. Both ADCVI and percent ADCC killing prechallenge were significantly correlated with reduced acute viremia. The latter, as well as postchallenge ADCVI and ADCC, was also significantly correlated with reduced chronic viremia. We have previously demonstrated induction by the prime/boost regimen of mucosal antibodies that inhibit transcytosis of SIV across an intact epithelial cell layer. Here, antibody in rectal secretions was significantly correlated with transcytosis inhibition. Importantly, the transcytosis specific activity (percent inhibition/total secretory IgA and IgG) was strongly correlated with reduced chronic viremia, suggesting that mucosal antibody may help control cell-to-cell viral spread during the course of infection. Overall, the replicating Ad5hr-HIV/SIV priming/gp140 protein boosting approach elicited strong systemic and mucosal antibodies with multiple functional activities associated with control of both acute and chronic viremia.

Citing Articles

SHIV-C109p5 NHP induces rapid disease progression in elderly macaques with extensive GI viral replication.

Bose D, Deb Adhikary N, Xiao P, Rogers K, Ferrell D, Cheng-Mayer C J Virol. 2024; 98(2):e0165223.

PMID: 38299866 PMC: 10878093. DOI: 10.1128/jvi.01652-23.

Cytokine Adjuvants IL-7 and IL-15 Improve Humoral Responses of a SHIV LentiDNA Vaccine in Animal Models.

Leroy L, Mac Donald A, Kandlur A, Bose D, Xiao P, Gagnon J Vaccines (Basel). 2022; 10(3).

PMID: 35335093 PMC: 8949948. DOI: 10.3390/vaccines10030461.

Vaccine-Induced, High-Magnitude HIV Env-Specific Antibodies with Fc-Mediated Effector Functions Are Insufficient to Protect Infant Rhesus Macaques against Oral SHIV Infection.

Curtis 2nd A, Saha P, Dennis M, Berendam S, Ramasubramanian P, Cross K mSphere. 2022; 7(1):e0083921.

PMID: 35196125 PMC: 8865927. DOI: 10.1128/msphere.00839-21.

Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV.

Wang S, Yates N, Pollara J, Voronin Y, Stanfield-Oakley S, Han D NPJ Vaccines. 2022; 7(1):18.

PMID: 35140230 PMC: 8828892. DOI: 10.1038/s41541-022-00441-9.

Assessment of an LSDV-Vectored Vaccine for Heterologous Prime-Boost Immunizations against HIV.

Chapman R, van Diepen M, Douglass N, Galant S, Jaffer M, Margolin E Vaccines (Basel). 2021; 9(11).

PMID: 34835214 PMC: 8620012. DOI: 10.3390/vaccines9111281.

References

McDermott A, Mitchen J, Piaskowski S, De Souza I, Yant L, Stephany J . Repeated low-dose mucosal simian immunodeficiency virus SIVmac239 challenge results in the same viral and immunological kinetics as high-dose challenge: a model for the evaluation of vaccine efficacy in nonhuman primates. J Virol. 2004; 78(6):3140-4. PMC: 353751. DOI: 10.1128/jvi.78.6.3140-3144.2004. View

Delgado M, Coviello S, Monsalvo A, Melendi G, Hernandez J, Batalle J . Lack of antibody affinity maturation due to poor Toll-like receptor stimulation leads to enhanced respiratory syncytial virus disease. Nat Med. 2008; 15(1):34-41. PMC: 2987729. DOI: 10.1038/nm.1894. View

Florese R, Van Rompay K, Aldrich K, Forthal D, Landucci G, Mahalanabis M . Evaluation of passively transferred, nonneutralizing antibody-dependent cellular cytotoxicity-mediating IgG in protection of neonatal rhesus macaques against oral SIVmac251 challenge. J Immunol. 2006; 177(6):4028-36. DOI: 10.4049/jimmunol.177.6.4028. View

Walker B, Burton D . Toward an AIDS vaccine. Science. 2008; 320(5877):760-4. DOI: 10.1126/science.1152622. View

Lubeck M, Natuk R, Myagkikh M, Kalyan N, Aldrich K, Sinangil F . Long-term protection of chimpanzees against high-dose HIV-1 challenge induced by immunization. Nat Med. 1997; 3(6):651-8. DOI: 10.1038/nm0697-651. View

Berek C, Berger A, Apel M . Maturation of the immune response in germinal centers. Cell. 1991; 67(6):1121-9. DOI: 10.1016/0092-8674(91)90289-b. View

Karnasuta C, Paris R, Cox J, Nitayaphan S, Pitisuttithum P, Thongcharoen P . Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine. 2005; 23(19):2522-9. DOI: 10.1016/j.vaccine.2004.10.028. View

Nag P, Kim J, Sapiega V, Landay A, Bremer J, Mestecky J . Women with cervicovaginal antibody-dependent cell-mediated cytotoxicity have lower genital HIV-1 RNA loads. J Infect Dis. 2004; 190(11):1970-8. PMC: 3119045. DOI: 10.1086/425582. View

Mascola J, Lewis M, Stiegler G, Harris D, Vancott T, Hayes D . Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999; 73(5):4009-18. PMC: 104180. DOI: 10.1128/JVI.73.5.4009-4018.1999. View

10.

Bogers W, Davis D, Baak I, Kan E, Hofman S, Sun Y . Systemic neutralizing antibodies induced by long interval mucosally primed systemically boosted immunization correlate with protection from mucosal SHIV challenge. Virology. 2008; 382(2):217-25. PMC: 2723753. DOI: 10.1016/j.virol.2008.09.016. View

11.

Malkevitch N, Patterson L, Aldrich M, Wu Y, Venzon D, Florese R . Durable protection of rhesus macaques immunized with a replicating adenovirus-SIV multigene prime/protein boost vaccine regimen against a second SIVmac251 rectal challenge: role of SIV-specific CD8+ T cell responses. Virology. 2006; 353(1):83-98. DOI: 10.1016/j.virol.2006.05.012. View

12.

Forthal D, Moog C . Fc receptor-mediated antiviral antibodies. Curr Opin HIV AIDS. 2010; 4(5):388-93. PMC: 2882066. DOI: 10.1097/COH.0b013e32832f0a89. View

13.

Shattock R, Griffin G, Gorodeski G . In vitro models of mucosal HIV transmission. Nat Med. 2000; 6(6):607-8. DOI: 10.1038/76138. View

14.

Robey F, Robert-Guroff M, Batinic D, Ivanov B, Lewis M, Roller P . A synthetic conformational epitope from the C4 domain of HIV Gp120 that binds CD4. J Biol Chem. 1996; 271(30):17990-5. DOI: 10.1074/jbc.271.30.17990. View

15.

Meng G, Wei X, Wu X, Sellers M, Decker J, Moldoveanu Z . Primary intestinal epithelial cells selectively transfer R5 HIV-1 to CCR5+ cells. Nat Med. 2002; 8(2):150-6. DOI: 10.1038/nm0202-150. View

16.

Gomez-Roman V, Florese R, Patterson L, Peng B, Venzon D, Aldrich K . A simplified method for the rapid fluorometric assessment of antibody-dependent cell-mediated cytotoxicity. J Immunol Methods. 2005; 308(1-2):53-67. DOI: 10.1016/j.jim.2005.09.018. View

17.

Barouch D . Challenges in the development of an HIV-1 vaccine. Nature. 2008; 455(7213):613-9. PMC: 2572109. DOI: 10.1038/nature07352. View

18.

Baba T, Liska V, Hofmann-Lehmann R, Vlasak J, Xu W, Ayehunie S . Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med. 2000; 6(2):200-6. DOI: 10.1038/72309. View

19.

Hansen S, Vieville C, Whizin N, Coyne-Johnson L, Siess D, Drummond D . Effector memory T cell responses are associated with protection of rhesus monkeys from mucosal simian immunodeficiency virus challenge. Nat Med. 2009; 15(3):293-9. PMC: 2720091. DOI: 10.1038/nm.1935. View

20.

Bertley F, Kozlowski P, Wang S, Chappelle J, Patel J, Sonuyi O . Control of simian/human immunodeficiency virus viremia and disease progression after IL-2-augmented DNA-modified vaccinia virus Ankara nasal vaccination in nonhuman primates. J Immunol. 2004; 172(6):3745-57. DOI: 10.4049/jimmunol.172.6.3745. View